{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T19:17:26Z","timestamp":1793733446253,"version":"4.6.1"},"reference-count":88,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,20]],"date-time":"2025-12-20T00:00:00Z","timestamp":1766188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T00:00:00Z","timestamp":1766966400000},"content-version":"vor","delay-in-days":9,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["No. 81704054"],"award-info":[{"award-number":["No. 81704054"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Exp Clin Cancer Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Hepatocellular carcinoma (HCC), often arising from liver fibrosis in nonalcoholic fatty liver disease (NAFLD), remains a leading cause of cancer-related death. Targeting the gut\u2013liver axis offers new therapeutic opportunities to prevent this progression. In this study, colon-targeted chitosan\/pectin-based nanoparticles loaded with Astragalus polysaccharide (APs-CS\/PT-NPs) were developed to modulate gut microbiota and inhibit liver tumorigenesis. The nanoparticles exhibited robust physicochemical stability and pH-responsive release. In vivo, oral administration of APs-CS\/PT-NPs attenuated hepatic steatosis, reduced inflammatory cytokines, and suppressed NAFLD-induced HCC development. 16\u00a0S rRNA sequencing revealed restoration of microbial diversity and enhanced production of short-chain fatty acids, especially acetate. Mechanistically, transcriptomic profiling and functional analysis identified acetate as a key mediator, acting via G-protein-coupled receptor 43 (GPR43) to inhibit the NF-\u03baB pathway. These results highlight the therapeutic potential of APs-CS\/PT-NPs in modulating the gut\u2013liver axis, rebalancing intestinal microbiota, and suppressing pro-inflammatory signaling. This nanoparticle-based strategy offers a promising food-derived preventive intervention for liver fibrosis\u2013HCC transition.<\/jats:p>\n                  <jats:p>\n                    <jats:bold>Graphical Abstract<\/jats:bold>\n                  <\/jats:p>","DOI":"10.1186\/s13046-025-03608-z","type":"journal-article","created":{"date-parts":[[2025,12,20]],"date-time":"2025-12-20T08:43:56Z","timestamp":1766220236000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Colon-Targeted astragalus polysaccharide nanoparticles prevent NAFLD-Driven hepatocarcinogenesis via microbiota remodeling and NF-\u03baB Inhibition"],"prefix":"10.1186","volume":"44","author":[{"given":"Dan","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Runtian","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingzhu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pengling","family":"Ge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,20]]},"reference":[{"key":"3608_CR1","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1097\/HEP.0000000000000004","volume":"77","author":"ZM Younossi","year":"2023","unstructured":"Younossi ZM, Golabi P, Paik JM, Henry A, Van Dongen C, Henry L. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology. 2023;77:1335\u201347.","journal-title":"Hepatology"},{"key":"3608_CR2","doi-asserted-by":"publisher","first-page":"S5","DOI":"10.3350\/cmh.2022.0424","volume":"29","author":"SK Han","year":"2023","unstructured":"Han SK, Baik SK, Kim MY. Non-alcoholic fatty liver disease: definition and subtypes. Clin Mol Hepatol. 2023;29:S5\u201316.","journal-title":"Clin Mol Hepatol"},{"key":"3608_CR3","doi-asserted-by":"crossref","unstructured":"Hepatocellular carcinoma (HCC). Epidemiology, etiology and molecular classification. Adv Cancer Res. 2021;149:1-61.","DOI":"10.1016\/bs.acr.2020.10.001"},{"key":"3608_CR4","doi-asserted-by":"publisher","first-page":"5529","DOI":"10.1093\/nar\/gkw462","volume":"44","author":"S Lee","year":"2016","unstructured":"Lee S, Mardinoglu A, Zhang C, Lee D, Nielsen J. Dysregulated signaling hubs of liver lipid metabolism reveal hepatocellular carcinoma pathogenesis. Nucleic Acids Res. 2016;44:5529\u201339.","journal-title":"Nucleic Acids Res"},{"key":"3608_CR5","doi-asserted-by":"publisher","DOI":"10.1111\/cpr.12772","author":"B Hu","year":"2020","unstructured":"Hu B, Lin J, Yang X, Sang X. Aberrant lipid metabolism in hepatocellular carcinoma cells as well as immune microenvironment: a review. Cell Prolif. 2020. https:\/\/doi.org\/10.1111\/cpr.12772.","journal-title":"Cell Prolif"},{"key":"3608_CR6","doi-asserted-by":"publisher","first-page":"5155","DOI":"10.1038\/s41388-021-01950-y","volume":"40","author":"MK Brahma","year":"2021","unstructured":"Brahma MK, Gilglioni EH, Zhou L, Tr\u00e9po E, Chen P, Gurzov EN. Oxidative stress in obesity-associated hepatocellular carcinoma: sources, signaling and therapeutic challenges. Oncogene. 2021;40:5155\u201367.","journal-title":"Oncogene"},{"key":"3608_CR7","doi-asserted-by":"publisher","DOI":"10.31083\/j.fbl2811286","author":"Y Li","year":"2023","unstructured":"Li Y, Yu Y, Yang L, Wang R. Insights into the role of oxidative stress in hepatocellular carcinoma development. Front Biosci (Landmark Ed). 2023. https:\/\/doi.org\/10.31083\/j.fbl2811286.","journal-title":"Front. Biosci. (Landmark Ed)"},{"key":"3608_CR8","doi-asserted-by":"publisher","first-page":"2434","DOI":"10.3748\/wjg.v27.i20.2434","volume":"27","author":"L-C Chen","year":"2021","unstructured":"Chen L-C, Lin H-Y, Hung S-K, Chiou W-Y, Lee M-S. Role of modern radiotherapy in managing patients with hepatocellular carcinoma. WJG. 2021;27:2434\u201357.","journal-title":"WJG"},{"key":"3608_CR9","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-020-00264-x","author":"A Huang","year":"2020","unstructured":"Huang A, Yang X-R, Chung W-Y, Dennison AR, Zhou J. Targeted therapy for hepatocellular carcinoma. Sig Transduct Target Ther. 2020. https:\/\/doi.org\/10.1038\/s41392-020-00264-x.","journal-title":"Sig Transduct Target Ther"},{"key":"3608_CR10","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.3748\/wjg.v29.i6.1054","volume":"29","author":"DS Mandlik","year":"2023","unstructured":"Mandlik DS, Mandlik SK, Choudhary HB. Immunotherapy for hepatocellular carcinoma: current status and future perspectives. World J Gastroenterol. 2023;29:1054\u201375.","journal-title":"World J Gastroenterol"},{"key":"3608_CR11","doi-asserted-by":"publisher","DOI":"10.1080\/19490976.2023.2240031","author":"J Rajapakse","year":"2023","unstructured":"Rajapakse J, Khatiwada S, Akon AC, Yu KL, Shen S, Zekry A. Unveiling the complex relationship between gut microbiota and liver cancer: opportunities for novel therapeutic interventions. Gut Microbes. 2023. https:\/\/doi.org\/10.1080\/19490976.2023.2240031.","journal-title":"Gut Microbes"},{"key":"3608_CR12","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2023.1140126","author":"S Liu","year":"2023","unstructured":"Liu S, Yang X. Intestinal flora plays a role in the progression of hepatitis-cirrhosis-liver cancer. Front Cell Infect Microbiol. 2023. https:\/\/doi.org\/10.3389\/fcimb.2023.1140126.","journal-title":"Front. Cell. Infect. Microbiol"},{"key":"3608_CR13","doi-asserted-by":"publisher","first-page":"113","DOI":"10.4236\/jbm.2022.1011010","volume":"10","author":"Q Tang","year":"2022","unstructured":"Tang Q, Tang M. Gut microbiota and metabolic diseases. JBM. 2022;10:113\u201341.","journal-title":"JBM"},{"key":"3608_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-16189-5","author":"K Nishitsuji","year":"2017","unstructured":"Nishitsuji K, Xiao J, Nagatomo R, Umemoto H, Morimoto Y, Akatsu H, et al. Analysis of the gut microbiome and plasma short-chain fatty acid profiles in a spontaneous mouse model of metabolic syndrome. Sci Rep. 2017. https:\/\/doi.org\/10.1038\/s41598-017-16189-5.","journal-title":"Sci Rep"},{"key":"3608_CR15","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-016-0303-2","author":"CL Boulang\u00e9","year":"2016","unstructured":"Boulang\u00e9 CL, Neves AL, Chilloux J, Nicholson JK, Dumas M-E. Impact of the gut microbiota on inflammation, obesity, and metabolic disease. Genome Med. 2016. https:\/\/doi.org\/10.1186\/s13073-016-0303-2.","journal-title":"Genome Med"},{"key":"3608_CR16","doi-asserted-by":"publisher","first-page":"4050","DOI":"10.1172\/JCI129194","volume":"129","author":"K Dabke","year":"2019","unstructured":"Dabke K, Hendrick G, Devkota S. The gut microbiome and metabolic syndrome. J Clin Invest. 2019;129:4050\u20137.","journal-title":"J Clin Invest"},{"key":"3608_CR17","doi-asserted-by":"publisher","first-page":"104821","DOI":"10.1016\/j.ebiom.2023.104821","volume":"97","author":"L Crudele","year":"2023","unstructured":"Crudele L, Gadaleta RM, Cariello M, Moschetta A. Gut microbiota in the pathogenesis and therapeutic approaches of diabetes. eBioMedicine. 2023;97:104821.","journal-title":"eBioMedicine"},{"key":"3608_CR18","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.616506","author":"L Massier","year":"2021","unstructured":"Massier L, Bl\u00fcher M, Kovacs P, Chakaroun RM. Impaired intestinal barrier and tissue bacteria: pathomechanisms for metabolic diseases. Front Endocrinol. 2021. https:\/\/doi.org\/10.3389\/fendo.2021.616506.","journal-title":"Front Endocrinol"},{"key":"3608_CR19","doi-asserted-by":"publisher","DOI":"10.1186\/s12876-015-0311-5","author":"T-Y Zhao","year":"2015","unstructured":"Zhao T-Y, Su L-P, Ma C-Y, Zhai X-H, Duan Z-J, Zhu Y, et al. IGF-1 decreases portal vein endotoxin via regulating intestinal tight junctions and plays a role in attenuating portal hypertension of cirrhotic rats. BMC Gastroenterol. 2015. https:\/\/doi.org\/10.1186\/s12876-015-0311-5.","journal-title":"BMC Gastroenterol"},{"key":"3608_CR20","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1016\/j.jcmgh.2021.02.007","volume":"11","author":"S Ghosh","year":"2021","unstructured":"Ghosh S, Whitley CS, Haribabu B, Jala VR. Regulation of intestinal barrier function by microbial metabolites. Cell Mol Gastroenterol Hepatol. 2021;11:1463\u201382.","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"3608_CR21","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2019.00428","author":"AM Martin","year":"2019","unstructured":"Martin AM, Sun EW, Rogers GB, Keating DJ. The influence of the gut microbiome on host metabolism through the regulation of gut hormone release. Front Physiol. 2019. https:\/\/doi.org\/10.3389\/fphys.2019.00428.","journal-title":"Front Physiol"},{"key":"3608_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.114295","volume":"160","author":"Y Zhang","year":"2023","unstructured":"Zhang Y, Chen R, Zhang D, Qi S, Liu Y. Metabolite interactions between host and microbiota during health and disease: which feeds the other? Biomed Pharmacother. 2023;160:114295.","journal-title":"Biomed Pharmacother"},{"key":"3608_CR23","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1126\/science.1223813","volume":"336","author":"JK Nicholson","year":"2012","unstructured":"Nicholson JK, Holmes E, Kinross J, Burcelin R, Gibson G, Jia W, et al. Host-gut microbiota metabolic interactions. Science. 2012;336:1262\u20137.","journal-title":"Science"},{"key":"3608_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2024.116735","volume":"175","author":"D-H Lee","year":"2024","unstructured":"Lee D-H, Kim M-T, Han J-H. GPR41 and GPR43: from development to metabolic regulation. Biomed Pharmacother. 2024;175:116735.","journal-title":"Biomed Pharmacother"},{"key":"3608_CR25","first-page":"1","volume":"51","author":"M Xu","year":"2019","unstructured":"Xu M, Jiang Z, Wang C, Li N, Bo L, Zha Y, et al. Acetate attenuates inflammasome activation through GPR43-mediated Ca2+-dependent NLRP3 ubiquitination. Exp Mol Med. 2019;51:1\u201313.","journal-title":"Exp Mol Med"},{"key":"3608_CR26","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.3390\/cancers16081582","volume":"16","author":"S Zheng","year":"2024","unstructured":"Zheng S, Chan SW, Liu F, Liu J, Chow PKH, Toh HC, et al. Hepatocellular carcinoma: current drug therapeutic status, advances and challenges. Cancers. 2024;16:1582.","journal-title":"Cancers"},{"key":"3608_CR27","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/s41573-020-0090-8","volume":"20","author":"MJ Mitchell","year":"2020","unstructured":"Mitchell MJ, Billingsley MM, Haley RM, Wechsler ME, Peppas NA, Langer R. Engineering precision nanoparticles for drug delivery. Nat Rev Drug Discov. 2020;20:101\u201324.","journal-title":"Nat Rev Drug Discov"},{"key":"3608_CR28","doi-asserted-by":"publisher","first-page":"1596","DOI":"10.3390\/polym15071596","volume":"15","author":"A Yusuf","year":"2023","unstructured":"Yusuf A, Almotairy ARZ, Henidi H, Alshehri OY, Aldughaim MS. Nanoparticles as drug delivery systems: a review of the implication of nanoparticles\u2019 physicochemical properties on responses in biological systems. Polymers. 2023;15:1596.","journal-title":"Polymers"},{"key":"3608_CR29","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1164\/rccm.200504-613PP","volume":"172","author":"S Gelperina","year":"2005","unstructured":"Gelperina S, Kisich K, Iseman MD, Heifets L. The potential advantages of nanoparticle drug delivery systems in chemotherapy of tuberculosis. Am J Respir Crit Care Med. 2005;172:1487\u201390.","journal-title":"Am J Respir Crit Care Med"},{"key":"3608_CR30","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2020.00193","author":"Y Yao","year":"2020","unstructured":"Yao Y, Zhou Y, Liu L, Xu Y, Chen Q, Wang Y, et al. Nanoparticle-based drug delivery in cancer therapy and its role in overcoming drug resistance. Front Mol Biosci. 2020. https:\/\/doi.org\/10.3389\/fmolb.2020.00193.","journal-title":"Front Mol Biosci"},{"key":"3608_CR31","doi-asserted-by":"publisher","first-page":"123838","DOI":"10.1016\/j.ijpharm.2024.123838","volume":"652","author":"A Abdollahy","year":"2024","unstructured":"Abdollahy A, Salehi M, Mahami S, Bernkop-Schn\u00fcrch A, Vahedi H, Gharravi AM, et al. Therapeutic effect of 5-ASA and hesperidin-loaded chitosan\/Eudragit\u00ae S100 nanoparticles as a pH-sensitive carrier for local targeted drug delivery in a rat model of ulcerative colitis. Int J Pharm. 2024;652:123838.","journal-title":"Int J Pharm"},{"key":"3608_CR32","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.ijbiomac.2021.06.088","volume":"185","author":"D Li","year":"2021","unstructured":"Li D, Li J, Dong H, Li X, Zhang J, Ramaswamy S, et al. Pectin in biomedical and drug delivery applications: a review. Int J Biol Macromol. 2021;185:49\u201365.","journal-title":"Int J Biol Macromol"},{"key":"3608_CR33","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-84322-2","author":"C Wu","year":"2025","unstructured":"Wu C, Bi C, Kim G, Yang Z, Li S, Dai T, et al. Oral colon-targeted responsive chitosan\/pectin-based nanoparticles propels the application of tofacitinib in colitis therapy. Sci Rep. 2025. https:\/\/doi.org\/10.1038\/s41598-024-84322-2.","journal-title":"Sci Rep"},{"key":"3608_CR34","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.701003","author":"Q Zhuang","year":"2021","unstructured":"Zhuang Q, Ye X, Shen S, Cheng J, Shi Y, Wu S, et al. Astragalus polysaccharides ameliorate diet-induced gallstone formation by modulating synthesis of bile acids and the gut microbiota. Front Pharmacol. 2021. https:\/\/doi.org\/10.3389\/fphar.2021.701003.","journal-title":"Front Pharmacol"},{"key":"3608_CR35","doi-asserted-by":"publisher","DOI":"10.1007\/s42114-024-01046-7","author":"X Wang","year":"2024","unstructured":"Wang X, Li M, Yu F, Hou L, Cao R, Zhang L, et al. Astragalus polysaccharide inhibits lipogenesis in HFD-fed mice by suppressing LIPG via upregulation of UDPG. Adv Compos Hybrid Mater. 2024. https:\/\/doi.org\/10.1007\/s42114-024-01046-7.","journal-title":"Adv Compos Hybrid Mater"},{"key":"3608_CR36","doi-asserted-by":"publisher","first-page":"2688","DOI":"10.3390\/foods10112688","volume":"10","author":"J Zhou","year":"2021","unstructured":"Zhou J, Zhang N, Zhao L, Wu W, Zhang L, Zhou F, et al. Astragalus polysaccharides and saponins alleviate liver injury and regulate gut microbiota in alcohol liver disease mice. Foods. 2021;10:2688.","journal-title":"Foods"},{"key":"3608_CR37","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.eng.2020.05.023","volume":"9","author":"B Li","year":"2022","unstructured":"Li B, Hong Y, Gu Y, Ye S, Hu K, Yao J, et al. Functional metabolomics reveals that astragalus polysaccharides improve lipids metabolism through microbial metabolite 2-hydroxybutyric acid in obese mice. Engineering. 2022;9:111\u201322.","journal-title":"Engineering"},{"key":"3608_CR38","doi-asserted-by":"publisher","first-page":"2","DOI":"10.13652\/j.spjx.1003.5788.2024.80176","volume":"1","author":"Yuzhao Kang","year":"2025","unstructured":"Kang Yuzhao, Tao Shuutong, Deng Sihui. Preparation, characterization, and stability of chitosan\/arabic gum nanoemulsion. Food and Machinery. 2025;1:2\u20138. https:\/\/doi.org\/10.13652\/j.spjx.1003.5788.2024.80176.","journal-title":"Food and Machinery"},{"key":"3608_CR39","doi-asserted-by":"publisher","DOI":"10.27026\/d.cnki.ggszc.2022.000107","author":"Ran Xin","year":"2022","unstructured":"Ran Xin. Study on ultrafiltration purification process of astragalus aqueous extract by ceramic membrane [D]. Gansu Univ Chin Med. 2022. https:\/\/doi.org\/10.27026\/d.cnki.ggszc.2022.000107.","journal-title":"Gansu Univ Chin Med"},{"issue":"7","key":"3608_CR40","doi-asserted-by":"publisher","first-page":"89","DOI":"10.19964\/j.issn.1006-4990.2022-0598","volume":"55","author":"D Zhang Peng","year":"2023","unstructured":"Zhang Peng D, Shanshan W, Yulu, et al. Synthesis and characterization of magnetic Xanthated Chitosan [J]. Inorg Salts Ind. 2023;55(7):89\u201396. https:\/\/doi.org\/10.19964\/j.issn.1006-4990.2022-0598.","journal-title":"Inorg Salts Ind"},{"key":"3608_CR41","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/7042105","author":"X Xiao","year":"2018","unstructured":"Xiao X, Lu Z, Lin V, May A, Shaw DH, Wang Z, et al. MicroRNA miR-24\u20103p reduces apoptosis and regulates Keap1\u2010Nrf2 pathway in mouse cardiomyocytes responding to ischemia\/reperfusion injury. Oxid Med Cell Longev. 2018. https:\/\/doi.org\/10.1155\/2018\/7042105.","journal-title":"Oxid Med Cell Longev"},{"key":"3608_CR42","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-017-0738-0","author":"H Li","year":"2017","unstructured":"Li H, Wang X, Wen C, Huo Z, Wang W, Zhan Q, et al. Long noncoding RNA NORAD, a novel competing endogenous RNA, enhances the hypoxia-induced epithelial-mesenchymal transition to promote metastasis in pancreatic cancer. Mol Cancer. 2017. https:\/\/doi.org\/10.1186\/s12943-017-0738-0.","journal-title":"Mol Cancer"},{"key":"3608_CR43","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1002\/hep.32449","volume":"77","author":"C Hu","year":"2022","unstructured":"Hu C, Xu B, Wang X, Wan W, Lu J, Kong D, et al. Gut microbiota\u2013derived short-chain fatty acids regulate group 3 innate lymphoid cells in HCC. Hepatology. 2022;77:48\u201364.","journal-title":"Hepatology"},{"key":"3608_CR44","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.ado7438","author":"L Huang","year":"2024","unstructured":"Huang L, Hu W, Huang LQ, Zhou QX, Song ZY, Tao HY, et al. \u201cTwo-birds-one-stone\u201d oral nanotherapeutic designed to target intestinal integrins and regulate redox homeostasis for UC treatment. Sci Adv. 2024. https:\/\/doi.org\/10.1126\/sciadv.ado7438.","journal-title":"Sci Adv"},{"key":"3608_CR45","doi-asserted-by":"publisher","first-page":"8993","DOI":"10.2147\/IJN.S510937","volume":"Volume 20","author":"X Huang","year":"2025","unstructured":"Huang X, Yang J, Hu Y, Li S, Cai Z, Li C, et al. Protective effects of GalNac-modified red blood cell-derived extracellular vesicles against liver diseases. IJN. 2025;Volume 20:8993\u20139017.","journal-title":"IJN"},{"key":"3608_CR46","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1016\/j.jhep.2023.07.005","volume":"79","author":"Q Song","year":"2023","unstructured":"Song Q, Zhang X, Liu W, Wei H, Liang W, Zhou Y, et al. Bifidobacterium pseudolongum-generated acetate suppresses non-alcoholic fatty liver disease-associated hepatocellular carcinoma. J Hepatol. 2023;79:1352\u201365.","journal-title":"J Hepatol"},{"key":"3608_CR47","doi-asserted-by":"publisher","DOI":"10.1111\/jcmm.70785","author":"S Ye","year":"2025","unstructured":"Ye S, Liufu C, Yin C, Zhu T, He J, Tian Y, et al. MiR-20a\u20105p inhibits bladder cancer proliferation and migration by targeting KPNA2. J Cell Mol Med. 2025. https:\/\/doi.org\/10.1111\/jcmm.70785.","journal-title":"J Cell Mol Med"},{"key":"3608_CR48","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.jconrel.2024.01.051","volume":"367","author":"Y Zhao","year":"2024","unstructured":"Zhao Y, Yin W, Yang Z, Sun J, Chang J, Huang L, et al. Nanotechnology-enabled M2 macrophage polarization and ferroptosis inhibition for targeted inflammatory bowel disease treatment. J Control Release. 2024;367:339\u201353.","journal-title":"J Control Release"},{"key":"3608_CR49","doi-asserted-by":"publisher","DOI":"10.27170\/d.cnki.gjsuu.2024.001922","author":"S Wang","year":"2024","unstructured":"Wang S. Study on the alleviating effect and mechanism of L-lactic acid on DSS-induced colitis in mice [D]. Jiangsu Univ. 2024. https:\/\/doi.org\/10.27170\/d.cnki.gjsuu.2024.001922.","journal-title":"Jiangsu Univ"},{"key":"3608_CR50","doi-asserted-by":"publisher","first-page":"6591","DOI":"10.3748\/wjg.v21.i21.6591","volume":"21","author":"X-F Lu","year":"2015","unstructured":"Lu X-F. Loss of Dicer1 impairs hepatocyte survival and leads to chronic inflammation and progenitor cell activation. WJG. 2015;21:6591.","journal-title":"WJG"},{"key":"3608_CR51","doi-asserted-by":"publisher","first-page":"e008094","DOI":"10.1136\/jitc-2023-008094","volume":"12","author":"F Zhang","year":"2024","unstructured":"Zhang F, Liu W, Meng F, Jiang Q, Tang W, Liu Z, et al. Inhibiting PLA2G7 reverses the immunosuppressive function of intratumoral macrophages and augments immunotherapy response in hepatocellular carcinoma. J Immunother Cancer. 2024;12:e008094.","journal-title":"J Immunother Cancer"},{"key":"3608_CR52","doi-asserted-by":"publisher","DOI":"10.1111\/cns.70417","author":"S Huang","year":"2025","unstructured":"Huang S, Wang X, Wang M, Lin J, Ren J, Lu C, et al. S-9\u2010PAHSA protects against high\u2010fat diet\u2010induced diabetes\u2010associated cognitive impairment via gut microbiota regulation. CNS Neurosci Ther. 2025. https:\/\/doi.org\/10.1111\/cns.70417.","journal-title":"CNS Neurosci Ther"},{"key":"3608_CR53","doi-asserted-by":"publisher","first-page":"155492","DOI":"10.1016\/j.phymed.2024.155492","volume":"128","author":"H Wang","year":"2024","unstructured":"Wang H, Zhu W, Hong Y, Wei W, Zheng N, He X, et al. Astragalus polysaccharides attenuate chemotherapy-induced immune injury by modulating gut microbiota and polyunsaturated fatty acid metabolism. Phytomedicine. 2024;128:155492.","journal-title":"Phytomedicine"},{"key":"3608_CR54","doi-asserted-by":"publisher","DOI":"10.1016\/j.carbpol.2024.122829","volume":"349","author":"Y Zhang","year":"2025","unstructured":"Zhang Y, Ji W, Qin H, Chen Z, Zhou Y, Zhou Z, et al. Astragalus polysaccharides alleviate DSS-induced ulcerative colitis in mice by restoring SCFA production and regulating Th17\/Treg cell homeostasis in a microbiota-dependent manner. Carbohydr Polym. 2025;349:122829.","journal-title":"Carbohydr Polym"},{"key":"3608_CR55","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1243834","author":"M Su","year":"2023","unstructured":"Su M, Tang T, Tang W, Long Y, Wang L, Liu M. Astragalus improves intestinal barrier function and immunity by acting on intestinal microbiota to treat T2DM: a research review. Front Immunol. 2023. https:\/\/doi.org\/10.3389\/fimmu.2023.1243834.","journal-title":"Front Immunol"},{"key":"3608_CR56","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.1018557","author":"J Liu","year":"2022","unstructured":"Liu J, Kong L, Shao M, Sun C, Li C, Wang Y, et al. Seabuckthorn polysaccharide combined with astragalus polysaccharide ameliorate alcoholic fatty liver by regulating intestinal flora. Front Endocrinol. 2022. https:\/\/doi.org\/10.3389\/fendo.2022.1018557.","journal-title":"Front Endocrinol"},{"key":"3608_CR57","doi-asserted-by":"publisher","DOI":"10.1080\/19490976.2024.2331460","author":"R Bened\u00e9-Ubieto","year":"2024","unstructured":"Bened\u00e9-Ubieto R, Cubero FJ, Nevzorova YA. Breaking the barriers: the role of gut homeostasis in Metabolic-Associated Steatotic Liver Disease (MASLD). Gut Microbes. 2024. https:\/\/doi.org\/10.1080\/19490976.2024.2331460.","journal-title":"Gut Microbes"},{"key":"3608_CR58","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.3390\/nu15061323","volume":"15","author":"A Gudan","year":"2023","unstructured":"Gudan A, Koz\u0142owska-Petriczko K, Wunsch E, Bodnarczuk T, Stachowska E. Small intestinal bacterial overgrowth and non-alcoholic fatty liver disease: what do we know in 2023? Nutrients. 2023;15:1323.","journal-title":"Nutrients"},{"key":"3608_CR59","doi-asserted-by":"publisher","first-page":"524","DOI":"10.3390\/biomedicines10030524","volume":"10","author":"Q Song","year":"2022","unstructured":"Song Q, Zhang X. The role of gut\u2013Liver axis in gut microbiome dysbiosis associated NAFLD and NAFLD-HCC. Biomedicines. 2022;10:524.","journal-title":"Biomedicines"},{"key":"3608_CR60","doi-asserted-by":"publisher","DOI":"10.1016\/j.foodchem.2022.135361","volume":"410","author":"B Han","year":"2023","unstructured":"Han B, Zhai Y, Li X, Zhao H, Sun C, Zeng Y, et al. Total flavonoids of Tetrastigma hemsleyanum Diels et Gilg inhibits colorectal tumor growth by modulating gut microbiota and metabolites. Food Chem. 2023;410:135361.","journal-title":"Food Chem"},{"key":"3608_CR61","doi-asserted-by":"publisher","first-page":"4050","DOI":"10.1111\/cas.15078","volume":"112","author":"G Ding","year":"2021","unstructured":"Ding G, Gong Q, Ma J, Liu X, Wang Y, Cheng X. Immunosuppressive activity is attenuated by astragalus polysaccharides through remodeling the gut microenvironment in melanoma mice. Cancer Sci. 2021;112:4050\u201363.","journal-title":"Cancer Sci"},{"key":"3608_CR62","doi-asserted-by":"publisher","unstructured":"Vazquez-Gutierrez P, de Wouters T, Werder J, Chassard C, Lacroix C. High Iron-Sequestrating bifidobacteria inhibit enteropathogen growth and adhesion to intestinal epithelial cells in vitro. Front Microbiol. 2016;7. https:\/\/doi.org\/10.3389\/fmicb.2016.01480.","DOI":"10.3389\/fmicb.2016.01480"},{"key":"3608_CR63","doi-asserted-by":"publisher","DOI":"10.1080\/19490976.2021.1930874","author":"Y Hong","year":"2021","unstructured":"Hong Y, Sheng L, Zhong J, Tao X, Zhu W, Ma J, et al. Desulfovibrio vulgaris, a potent acetic acid-producing bacterium, attenuates nonalcoholic fatty liver disease in mice. Gut Microbes. 2021. https:\/\/doi.org\/10.1080\/19490976.2021.1930874.","journal-title":"Gut Microbes"},{"key":"3608_CR64","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1038\/nrgastro.2010.213","volume":"8","author":"T Luedde","year":"2011","unstructured":"Luedde T, Schwabe RF. NF-\u03baB in the liver\u2014linking injury, fibrosis and hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. 2011;8:108\u201318.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"3608_CR65","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2023.175594","volume":"944","author":"Y Wei","year":"2023","unstructured":"Wei Y, Qi M, Liu C, Li L. Astragalus polysaccharide attenuates bleomycin-induced pulmonary fibrosis by inhibiting TLR4\/ NF-\u03baB signaling pathway and regulating gut microbiota. Eur J Pharmacol. 2023;944:175594.","journal-title":"Eur J Pharmacol"},{"key":"3608_CR66","doi-asserted-by":"publisher","first-page":"458","DOI":"10.14348\/molcells.2021.0021","volume":"44","author":"B-O Park","year":"2021","unstructured":"Park B-O, Kim SH, Kim JH, Kim S-Y, Park BC, Han S-B, et al. The short-chain fatty acid receptor GPR43 modulates YAP\/TAZ via RhoA. Molecules Cells. 2021;44:458\u201367.","journal-title":"Molecules Cells"},{"key":"3608_CR67","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1188277","author":"M Zhao","year":"2023","unstructured":"Zhao M, Huang H, He F, Fu X. Current insights into the hepatic microenvironment and advances in immunotherapy for hepatocellular carcinoma. Front Immunol. 2023. https:\/\/doi.org\/10.3389\/fimmu.2023.1188277.","journal-title":"Front Immunol"},{"key":"3608_CR68","doi-asserted-by":"publisher","first-page":"e000394","DOI":"10.1136\/jitc-2019-000394","volume":"8","author":"WJ Ho","year":"2020","unstructured":"Ho WJ, Danilova L, Lim SJ, Verma R, Xavier S, Leatherman JM, et al. Viral status, immune microenvironment and immunological response to checkpoint inhibitors in hepatocellular carcinoma. J Immunother Cancer. 2020;8:e000394.","journal-title":"J Immunother Cancer"},{"key":"3608_CR69","doi-asserted-by":"publisher","DOI":"10.7554\/elife.95009","author":"Y Fu","year":"2024","unstructured":"Fu Y, Guo X, Sun L, Cui T, Wu C, Wang J, et al. Exploring the role of the immune microenvironment in hepatocellular carcinoma: implications for immunotherapy and drug resistance. eLife. 2024. https:\/\/doi.org\/10.7554\/elife.95009.","journal-title":"eLife"},{"key":"3608_CR70","doi-asserted-by":"publisher","first-page":"4875","DOI":"10.3390\/cancers15194875","volume":"15","author":"B Gok Yavuz","year":"2023","unstructured":"Gok Yavuz B, Datar S, Chamseddine S, Mohamed YI, LaPelusa M, Lee SS, et al. The gut microbiome as a biomarker and therapeutic target in hepatocellular carcinoma. Cancers. 2023;15:4875.","journal-title":"Cancers"},{"key":"3608_CR71","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1120515","author":"Z Chen","year":"2023","unstructured":"Chen Z, Ding C, Gu Y, He Y, Chen B, Zheng S, et al. Association between gut microbiota and hepatocellular carcinoma from 2011 to 2022: bibliometric analysis and global trends. Front Oncol. 2023. https:\/\/doi.org\/10.3389\/fonc.2023.1120515.","journal-title":"Front Oncol"},{"key":"3608_CR72","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.livres.2017.05.001","volume":"1","author":"JYL Chiang","year":"2017","unstructured":"Chiang JYL. Bile acid metabolism and signaling in liver disease and therapy. Liver Res. 2017;1:3\u20139.","journal-title":"Liver Res"},{"key":"3608_CR73","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1081334","author":"C Song","year":"2023","unstructured":"Song C, Long X, He J, Huang Y. Recent evaluation about inflammatory mechanisms in nonalcoholic fatty liver disease. Front Pharmacol. 2023. https:\/\/doi.org\/10.3389\/fphar.2023.1081334.","journal-title":"Front Pharmacol"},{"key":"3608_CR74","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2022.110609","volume":"39","author":"S Li","year":"2022","unstructured":"Li S, Yu J, Huber A, Kryczek I, Wang Z, Jiang L, et al. Metabolism drives macrophage heterogeneity in the tumor microenvironment. Cell Rep. 2022;39:110609.","journal-title":"Cell Rep"},{"key":"3608_CR75","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.01830","author":"V Lazar","year":"2018","unstructured":"Lazar V, Ditu L-M, Pircalabioru GG, Gheorghe I, Curutiu C, Holban AM, et al. Aspects of gut microbiota and immune system interactions in infectious diseases, immunopathology, and cancer. Front Immunol. 2018. https:\/\/doi.org\/10.3389\/fimmu.2018.01830.","journal-title":"Front Immunol"},{"key":"3608_CR76","doi-asserted-by":"publisher","DOI":"10.1186\/s43066-024-00327-6","author":"PA Jadhav","year":"2024","unstructured":"Jadhav PA, Thomas AB, Nanda RK, Chitlange SS. Correlation of non-alcoholic fatty liver disease and gut microflora: clinical reports and treatment options. Egypt Liver J. 2024. https:\/\/doi.org\/10.1186\/s43066-024-00327-6.","journal-title":"Egypt Liver J"},{"key":"3608_CR77","doi-asserted-by":"publisher","DOI":"10.3389\/fnut.2021.700058","author":"D Tokuhara","year":"2021","unstructured":"Tokuhara D. Role of the gut microbiota in regulating non-alcoholic fatty liver disease in children and adolescents. Front Nutr. 2021. https:\/\/doi.org\/10.3389\/fnut.2021.700058.","journal-title":"Front Nutr"},{"key":"3608_CR78","doi-asserted-by":"publisher","DOI":"10.1186\/s12964-023-01219-9","author":"D Zhang","year":"2023","unstructured":"Zhang D, Jian Y-P, Zhang Y-N, Li Y, Gu L-T, Sun H-H, et al. Short-chain fatty acids in diseases. Cell Commun Signal. 2023. https:\/\/doi.org\/10.1186\/s12964-023-01219-9.","journal-title":"Cell Commun Signal"},{"key":"3608_CR79","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/j.neo.2021.04.004","volume":"23","author":"N McBrearty","year":"2021","unstructured":"McBrearty N, Arzumanyan A, Bichenkov E, Merali S, Merali C, Feitelson M. Short chain fatty acids delay the development of hepatocellular carcinoma in HBx transgenic mice. Neoplasia. 2021;23:529\u201338.","journal-title":"Neoplasia"},{"key":"3608_CR80","doi-asserted-by":"publisher","first-page":"7379","DOI":"10.3390\/ijms25137379","volume":"25","author":"Y Du","year":"2024","unstructured":"Du Y, He C, An Y, Huang Y, Zhang H, Fu W, et al. The role of short chain fatty acids in inflammation and body health. IJMS. 2024;25:7379.","journal-title":"IJMS"},{"key":"3608_CR81","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1038\/s41423-023-00987-1","volume":"20","author":"CH Kim","year":"2023","unstructured":"Kim CH. Complex regulatory effects of gut microbial short-chain fatty acids on immune tolerance and autoimmunity. Cell Mol Immunol. 2023;20:341\u201350.","journal-title":"Cell Mol Immunol"},{"key":"3608_CR82","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00535-016-1242-9","volume":"52","author":"M Sun","year":"2016","unstructured":"Sun M, Wu W, Liu Z, Cong Y. Microbiota metabolite short chain fatty acids, GPCR, and inflammatory bowel diseases. J Gastroenterol. 2016;52:1\u20138.","journal-title":"J Gastroenterol"},{"key":"3608_CR83","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.115821","volume":"169","author":"Q Yan","year":"2023","unstructured":"Yan Q, Jia S, Li D, Yang J. The role and mechanism of action of microbiota-derived short-chain fatty acids in neutrophils: from the activation to becoming potential biomarkers. Biomed Pharmacother. 2023;169:115821.","journal-title":"Biomed Pharmacother"},{"key":"3608_CR84","doi-asserted-by":"publisher","DOI":"10.1186\/s40164-024-00539-x","author":"Y Yin","year":"2024","unstructured":"Yin Y, Feng W, Chen J, Chen X, Wang G, Wang S, et al. Immunosuppressive tumor microenvironment in the progression, metastasis, and therapy of hepatocellular carcinoma: from bench to bedside. Exp Hematol Oncol. 2024. https:\/\/doi.org\/10.1186\/s40164-024-00539-x.","journal-title":"Exp Hematol Oncol"},{"key":"3608_CR85","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-024-01549-2","author":"K-Y Shen","year":"2024","unstructured":"Shen K-Y, Zhu Y, Xie S-Z, Qin L-X. Immunosuppressive tumor microenvironment and immunotherapy of hepatocellular carcinoma: current status and prospectives. J Hematol Oncol. 2024. https:\/\/doi.org\/10.1186\/s13045-024-01549-2.","journal-title":"J Hematol Oncol"},{"key":"3608_CR86","doi-asserted-by":"publisher","first-page":"2623","DOI":"10.3390\/biomedicines11102623","volume":"11","author":"I Nenu","year":"2023","unstructured":"Nenu I, Toadere TM, Topor I, \u021aichindeleanu A, Bondor DA, Trella \u0218erban E, et al. Interleukin-6 in hepatocellular carcinoma: a dualistic point of view. Biomedicines. 2023;11:2623.","journal-title":"Biomedicines"},{"key":"3608_CR87","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1192597","author":"X Jin","year":"2023","unstructured":"Jin X, Zhao J, Li H, Zheng M, Shao J, Chen Z. Research trends and hot spots in global nanotechnology applications in liver cancer: a bibliometric and visual analysis (2000\u20132022). Front Oncol. 2023. https:\/\/doi.org\/10.3389\/fonc.2023.1192597.","journal-title":"Front Oncol"},{"key":"3608_CR88","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1438819","author":"L Cai","year":"2024","unstructured":"Cai L, Du Y, Xiong H, Zheng H. Application of nanotechnology in the treatment of hepatocellular carcinoma. Front Pharmacol. 2024. https:\/\/doi.org\/10.3389\/fphar.2024.1438819.","journal-title":"Front Pharmacol"}],"container-title":["Journal of Experimental &amp; Clinical Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13046-025-03608-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-025-03608-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-025-03608-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T22:01:54Z","timestamp":1767045714000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13046-025-03608-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,20]]},"references-count":88,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3608"],"URL":"https:\/\/doi.org\/10.1186\/s13046-025-03608-z","relation":{},"ISSN":["1756-9966"],"issn-type":[{"value":"1756-9966","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,20]]},"assertion":[{"value":"1 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All animal experiments were approved by the Animal Ethics Committee of College of Basic Medicine, Heilongjiang University of Chinese Medicine (No. 2025050915).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"330"}}